Dengue virus

Clinics in Laboratory Medicine

Volumn 30, Issue 1, 2010, Pages 149-160

  Ross, Ted M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Clinical diagnosis; Dengue virus; Flavivirus; Infection; Vaccines

Indexed keywords

ANALGESIC AGENT; ANTIPYRETIC AGENT; DENGUE VACCINE; DNA VACCINE; PARACETAMOL;

AEDES AEGYPTI; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG RESPONSE; EPIDEMIC; FEVER; FLUID THERAPY; HUMAN; INFECTION RISK; LABORATORY DIAGNOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VACCINATION; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; VIRUS VIRULENCE;

AEDES; ANIMALS; DENGUE; DENGUE VACCINES; DENGUE VIRUS; DIAGNOSIS, DIFFERENTIAL; HUMANS; INSECT VECTORS;

EID: 77953335511     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cll.2009.10.007     Document Type: Review

References (71)

1. Burke D.S., Monath T.P. Flaviviruses. Fields virology 2001, 1043-1125. Lippincott Williams & Wilkins, Philadelphia. D.M. Knipe, P.M. Howley (Eds.).
2. Halstead S.B. Pathogenesis of dengue: challenges to molecular biology. Science 1988, 239:476-481.
3. Monath T.P. Dengue: the risk to developed and developing countries. Proc Natl Acad Sci U S A 1994, 91:2395-2400.
4. Chambers T.J., Hahn C.S., Galler R., et al. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 1990, 44:649-688.
5. Tassaneetrithep B., Burgess T., Granelli-Piperno A., et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 2003, 197(7):823-829.
6. Heinz F., Auer G., Stiasny K., et al. The interactions of the flavivirus envelope proteins: implications for virus entry and release. Arch Virol 1994, 9(S):339-348.
7. Heinz F., Stiasny K., Puschner-Auer G., et al. Structural changes and functional control of the tick-borne encephalitis virus glycoprotein E by the heterodimeric association with the protein prM. Virology 1994, 198:109-117.
8. Mackenzie J.M., Jones M.K., Westaway E.G. Markers for trans-Golgi membranes and the intermediate compartment localize to induced membranes with distinct replication functions in flavivirus-infected cells. J Virol 1999, 73:9555-9567.
9. Solomon T., Mallewa M. Dengue and other emerging flaviviruses. J Infect 2001, 42:104-115.
10. Rothman A.L. Dengue: defining protective versus pathologic immunity. J Clin Invest 2004, 113:946-951.
11. Rothman A.L., Ennis F.A. Immunopathogenesis of Dengue hemorrhagic fever. Virology 1999, 257:1-6.
12. Halstead S.B., Simasthien P. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J Biol Med 1970, 42:276-292.
13. Halstead S.B., Nimmannitya S., Cohen S.N. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J Biol Med 1970, 42:311-328.
14. Halstead S.B. Global epidemiology of dengue hemorrhagic fever. Southeast Asian J Trop Med Public Health 1990, 21:636-641.
15. Kliks S.C., Nimmanitya S., Nisalak A., et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988, 38:411-419.
16. Kliks S.C., Nisalak A., Brandt W.E., et al. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989, 40:444-451.
17. Libraty D.H., Endy T.P., Houng H.S., et al. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185:1213-1221.
18. Vaughn D.W., Green S., Kalayanarooj S., et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
19. Leitmeyer K.C., Vaughn D.W., Watts D.M., et al. Dengue virus structural differences that correlate with pathogenesis. J Virol 1999, 73:4738-4747.
20. Cologna R., Rico-Hesse R. American genotype structures decrease dengue virus output from human monocytes and dendritic cells. J Virol 2003, 77:3929-3938.
21. Pryor M.J., Carr J.M., Hocking H., et al. Replication of dengue virus type 2 in human monocyte-derived macrophages: comparisons of isolates and recombinant viruses with substitutions at amino acid 390 in the envelope glycoprotein. Am J Trop Med Hyg 2001, 65:427-434.
22. Watts D.M., Porter K.R., Putvatana P., et al. Failure of secondary infection with American genotype dengue 2 to cause dengue haemorrhagic fever. Lancet 1999, 354:1431-1434.
23. Messer W.B., Vitarana U.T., Sivananthan K., et al. Epidemiology of dengue in Sri Lanka before and after the emergence of epidemic dengue hemorrhagic fever. Am J Trop Med Hyg 2002, 66:765-773.
24. Green S., Vaughn D.W., Kalayanarooj S., et al. Early immune activation in acute dengue illness is related to development of plasma leakage and disease severity. J Infect Dis 1999, 179:755-762.
25. Hober D., Poli L., Roblin B., et al. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med Hyg 1993, 48:324-331.
26. Hober D., Nguyen T.L., Shen L., et al. Tumor necrosis factor alpha levels in plasma and whole-blood culture in dengue-infected patients: relationship between virus detection and pre- existing specific antibodies. J Med Virol 1998, 54:210-218.
27. Hober D., Delannoy A.S., Benyoucef S., et al. High levels of sTNFR p75 and TNF alpha in dengue-infected patients. Microbiol Immunol 1996, 40:569-573.
28. Bethell D.B., Flobbe K., Cao X.T., et al. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J Infect Dis 1998, 177:778-782.
29. Mongkolsapaya J., Duangchinda T., Dejnirattisai W., et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J Immunol 2006, 176:3821-3829.
30. Mongkolsapaya J., Dejnirattisai W., Xu X.N., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003, 9:921-927.
31. Green S., Pichyangkul S., Vaughn D.W., et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue hemorrhagic fever. J Infect Dis 1999, 180:1429-1435.
32. *07-restricted epitope on the dengue NS3 protein correlate with disease severity. J Immunol 2002, 168:5959-5965.
33. Bashyam H.S., Green S., Rothman A.L. Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 2006, 176:2817-2824.
34. Schwartz E., Mileguir F., Grossman Z., et al. Evaluation of ELISA-based sero-diagnosis of dengue fever in travelers. J Clin Virol 2000, 19:169-173.
35. Schwartz E., Moskovitz A., Potasman I., et al. Changing epidemiology of dengue fever in travelers to Thailand. Eur J Clin Microbiol Infect Dis 2000, 19:784-786.
36. Flannery B., Pereira M.M., Velloso L.D.F., et al. Referral pattern of leptospirosis cases during a large urban epidemic of dengue. Am J Trop Med Hyg 2001, 65:657-663.
37. Watt G., Jongsakul K., Chouriyagune C., et al. Differentiating dengue virus infection from scrub typhus in Thai adults with fever. Am J Trop Med Hyg 2003, 68:536-538.
38. Karande S., Gandhi D., Kulkarni M., et al. Concurrent outbreak of leptospirosis and dengue in Mumbai, India, 2002. J Trop Pediatr 2005, 51:174-181.
39. Dietz V.J., Nieburg P., Gubler D.J., et al. Diagnosis of measles by clinical case definition in dengue-endemic areas: implications for measles surveillance and control. Bull World Health Organ 1992, 70:745-750.
40. Wilder-Smith A., Earnest A., Paton N.I. Use of simple laboratory features to distinguish the early stage of severe acute respiratory syndrome from dengue fever. Clin Infect Dis 2004, 39:1818-1823.
41. Wilder-Smith A., Foo W., Earnest A., et al. Seroepidemiology of dengue in the adult population of Singapore. Trop Med Int Health 2004, 9:305-308.
42. Sabin A.B. Research on dengue during World War II. Am J Trop Med Hyg 1952, 1:30-50.
43. Halstead S.B. Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 1974, 23:974-982.
44. Kaufman B.M., Summers P.L., Dubois D.R., et al. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1987, 36:427-434.
45. Bray M., Zhao B.T., Markoff L., et al. Mice immunized with recombinant vaccinia virus expressing dengue 4 virus structural proteins with or without nonstructural protein NS1 are protected against fatal dengue virus encephalitis. J Virol 1989, 63:2853-2856.
46. Kaufman B.M., Summers P.L., Dubois D.R., et al. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 1989, 41:576-580.
47. Pengsaa K., Luxemburger C., Sabchareon A., et al. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in thai children. J Infect Dis 2006, 194:1570-1576.
48. Russell P.K., Nisalak A., Sukhavachana P., et al. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99:285-290.
49. Crill W.D., Roehrig J.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 2001, 75:7769-7773.
50. Roehrig J.T., Bolin R.A., Kelly R.G. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology 1998, 246:317-328.
51. Garcia G., Arango M., Perez A.B., et al. Antibodies from patients with dengue viral infection mediate cellular cytotoxicity. J Clin Virol 2006, 37:53-57.
52. Laoprasopwattana K., Libraty D.H., Endy T.P., et al. Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. J Infect Dis 2005, 192:510-519.
53. Falgout B., Bray M., Schlesinger J.J., et al. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol 1990, 64:4356-4363.
54. Calvert A.E., Huang C.Y., Kinney R.M., et al. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J Gen Virol 2006, 87:339-346.
55. Bukowski J.F., Kurane I., Lai C.J., et al. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol 1989, 63:5086-5091.
56. Kurane I., Meager A., Ennis F.A. Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity. J Exp Med 1989, 170:763-775.
57. Munoz-Jordan J.L., Laurent-Rolle M., Ashour J., et al. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol 2005, 79:8004-8013.
58. Barrett A.D. Current status of flavivirus vaccines. Ann N Y Acad Sci 2001, 951:262-271.
59. Halstead S.B., Deen J. The future of dengue vaccines. Lancet 2002, 360:1243-1245.
60. Guirakhoo F., Arroyo J., Pugachev K.V., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001, 75:7290-7304.
61. Huang C.Y., Butrapet S., Pierro D.J., et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000, 74:3020-3028.
62. Durbin A.P., Karron R.A., Sun W., et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001, 65:405-413.
63. Markoff L., Pang X., Houng Hs H.S., et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 2002, 76:3318-3328.
64. Bhamarapravati N., Sutee Y. Live attenuated tetravalent dengue vaccine. Vaccine 2000, 18(Suppl 2):44-47.
65. Edelman R., Wasserman S.S., Bodison S.A., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003, 69:48-60.
66. Sun W., Edelman R., Kanesa-thasan N., et al. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am J Trop Med Hyg 2003, 69:24-31.
67. Khanam S., Etemad B., Khanna N., et al. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 2006, 74:266-277.
68. Mota J., Acosta M., Argotte R., et al. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 2005, 23:3469-3476.
69. Hermida L., Rodriguez R., Lazo L., et al. A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 2004, 115:41-49.
70. Simmons M., Nelson W.M., Wu S.J., et al. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 1998, 58:655-662.
71. Simmons M., Murphy G.S., Hayes C.G. Short report: Antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65:159-161.